Baxter International Inc.
BAX | NYSE
$23.00
-$0.50 (-2.13%)
At close: Oct 30, 2026, 4:00 PM ET
$23.17
+$0.17 (+0.74%)
Pre-market:
Nov 2, 2026, 7:33 AM ET
Company Profile
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
Key Executives
| Name | Position |
|---|---|
| Andrew Hider | Chief Executive Officer, President, Interim Group President of Medical Products & Therapies and Director |
| Anita A. Zielinski | Senior Vice President, Interim Chief Financial Officer, Chief Accounting Officer & Controller |
| Charles Patel | Senior Vice President & Chief Information Officer |
| Adriana Guiry | Senior Vice President of Baxter Growth & Performance System |
| Cynthia Carlisle | Executive Vice President & Chief Human Resources Officer |
| David S. Rosenbloom | Executive Vice President & General Counsel |
| James Teaff | President of Care & Connectivity Solutions |
| James W. Borzi | Executive Vice President & Chief Supply Chain Officer |
| Kevin Moran | Vice President & Head of Investor Relations |
| Maria Soriano | Group President of Infusion Therapies & Platforms |
| Piero Novello | Senior Vice President and President of International |
| Scott Kaplan | Senior Vice President of Quality, Regulatory & Patient Safety |
| Stacey Eisen | SVP, Chief Communications Officer & Corporate Marketing and President of Baxter Foundation |
| Steven Wallace | President of Advanced Surgery & Commercial Excellence |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 02, 2026 | 3 | Filing |
| Sep 18, 2026 | 3 | Filing |
| Sep 03, 2026 | 4 | Filing |
| Sep 03, 2026 | 4 | Filing |
| Sep 03, 2026 | 4 | Filing |
| Aug 19, 2026 | 8-K | Current Report |
| Aug 18, 2026 | 8-K | Current Report |
| Aug 04, 2026 | 8-K | Current Report |
| Aug 04, 2026 | 8-K | Current Report |
| Jul 30, 2026 | 10-Q | Quarterly Report |
Baxter International Inc.
| Country | United States |
| IPO Date | Oct 27, 1981 |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Employees | 37,500 |
| CEO | Andrew Hider |
Contact Details
One Baxter Parkway Deerfield,
Illinois 60015 United States
Stock Details
| Ticker Symbol | BAX |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000010456 |
| CUSIP Number | 071813109 |
| ISIN Number | US0718131099 |
| SIC Code | 3841 |
Recent News
- 3 days ago / marketbeat.comWhat Baxter International (BAX) Said on Its Q3 Earnings Call
- 3 days ago / zacks.comBaxter Q3 Earnings Beat on Broad-Based Growth, '26 Outlook Raised
- 3 days ago / seekingalpha.comBaxter International Inc. (BAX) Q3 2026 Earnings Call Transcript
- 3 days ago / benzinga.comWhy Is Baxter Stock Trading Lower on Thursday?
- 4 days ago / zacks.comCompared to Estimates, Baxter (BAX) Q3 Earnings: A Look at Key Metrics
- 4 days ago / zacks.comBaxter International (BAX) Q3 Earnings and Revenues Surpass Estimates
- 4 days ago / businesswire.comBaxter Reports Third-Quarter 2026 Results
- 6 days ago / zacks.comWill Baxter's Q3 Earnings Show Progress Despite Cost Pressures?
- 20 days ago / seekingalpha.comBaxter International: The Vantive Transition Complicates Margin Recovery
- 26 days ago / businesswire.comBaxter to Host Third-Quarter 2026 Financial Results Conference Call for Investors
Add to Watchlist
Select watchlists to add or remove BAX